Agenus Inc. · NASDAQ:AGEN

Agenus — Technical Presentation (June 2023)

17 slides from Agenus's technical presentation, June 2023

  1. Slide 1: World Congress on Gastrointestinal Cancer

    Slide 1: World Congress on Gastrointestinal Cancer

    WORLD CONGRESS ON ? Gastrointestinal Cancer 28 JUNE — 1JULY 20235 Barcelona, Spain

  2. Slide 2: Results from an expanded phase 1 trial of botensilimab plus balstilimab in MSS CRC

    Slide 2: Results from an expanded phase 1 trial of botensilimab plus balstilimab in MSS CRC

    Results from an expanded phase 1 trial of botensilimab, a multifunctional anti-CTLA-4, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer Andrea J. Bullock, MD, MPH1, Marwan G. Fakih, MD2, Michael S. Gordon, MD3, Apostolia M. Tsimberidou, MD, PhD4,

  3. Slide 3: Disclosures

    Slide 3: Disclosures

    DISCLOSURES Andrea J. Bullock Consulting fees: Exelixis, Panovance, Oncolytics The content of this presentation is the property of Andrea J. Bullock, licensed by ESMO GI. Permission is required for reuse. 2

  4. Slide 4: Botensilimab is a novel innate & adaptive immune activator

    Slide 4: Botensilimab is a novel innate & adaptive immune activator

    BOTENSILIMAB IS A NOVEL INNATE & ADAPTIVE IMMUNE ACTIVATOR Expanding the Reach of Immunotherapy botensilimab Driving Activity in Cold or I-O Refractory A Multifunctional Fc-enhanced Anti-CTLA-4 Tumors1-4 • Enhanced T cell priming, expansion, memory5,6 • Enhanced frequency of APCs • Enhanced Treg dep

  5. Slide 5: Balstilimab is a clinically validated PD-1 inhibitor

    Slide 5: Balstilimab is a clinically validated PD-1 inhibitor

    BALSTILIMAB IS A CLINICALLY VALIDATED PD-1 INHIBITOR balstilimab PD-1 Inhibitor A Highly Active Anti-PD-1 mAb1,2 • Complete blocker of PD-1- PD-L1/2 interactions • Enhanced T cell activation and effector function 1. O’Malley, et al. Gynecol Oncol. 2021; 163: 274-280. 2. O’Malley et al, J Clin Oncol.

  6. Slide 6: Study Design (C-800-01): Non-MSI-H CRC Cohort

    Slide 6: Study Design (C-800-01): Non-MSI-H CRC Cohort

    STUDY DESIGN (C-800-01): NON-MSI-H CRC COHORT NCT03860272: First-in-human trial of botensilimab (bot) ± balstilimab (bal) in patients with advanced cancer1 Key Eligibility Treatment (up to 2 years) • Refractory Metastatic CRC • MSS by local assessment Combination therapy • Prior I-O allowed bot + ba

  7. Slide 7: Patient Disposition

    Slide 7: Patient Disposition

    PATIENT DISPOSITION Intent-to-treat Population (ITT; All Treated Patients) Safety Evaluable 101 Non-MSI-H patients received ≥1 dose (1 or 2 mg/kg botensilimab Q6W + 3 mg/kg balstilimab Q2W) 77 with no active liver metastases 24 with active liver metastases 14 patients (including 6 with active liver

  8. Slide 8: Patient Characteristics

    Slide 8: Patient Characteristics

    PATIENT CHARACTERISTICS ITT Population ITT Population N=101 N=101 Age, median (range) 54 (25–82) Prior lines of therapy, n (%) Sex, n (%) Median (range)† 4 (1–10) Male 45 (45) ≥3 73 (72) Female 56 (55) Prior I-O, n (%)*‡ 25 (25) ECOG PS at baseline, n (%) TMB >10, mut/Mb, n/N (%)* 3/76 (4) 0 44 (44)

  9. Slide 9: Deep and Durable Objective Responses

    Slide 9: Deep and Durable Objective Responses

    DEEP AND DURABLE OBJECTIVE RESPONSES All EE No Active Liver Mets EE Active Liver Mets EE n=87* n=69† n=18‡ Confirmed ORR, n % (95% CI) 18% (11–28)​ 23% (14–35)​ 0% (0–19)​ BOR, n (%)​ CR​ 1 (1)​ 1 (1)​ 0​ PR​ 15 (17)​ 15 (22)​ 0 SD​ 45 (52)​ 39 (57)​ 6 (33)​ PD 26 (30)​ 14 (20)​ 12 (67)​ DCR (CR + P

  10. Slide 10: Deep Objective Responses

    Slide 10: Deep Objective Responses

    DEEP OBJECTIVE RESPONSES No Active Liver Metastases (Efficacy Evaluable, n=69*) 100 90 80 ORR DCR 23% 80% Best Percent Change From Baseline (%) 70 60 50 95% CI, 14-35 95% CI, 68-88 40 30 20% Tumor Growth 20 10 0 -10 -20 -30 -40 30% Tumor Reduction † † -50 † † † † † † -60 † † † † -70 -80 † † -90 -100

  11. Slide 11: Durable Objective Responses

    Slide 11: Durable Objective Responses

    DURABLE OBJECTIVE RESPONSES No Active Liver Metastases (Efficacy Evaluable, n=69*) 100 90 Ongoing Responses 11 of 16 (69%) Best Percent Change in Target Lesions (%) 80 70 Range, 1.4+ to 24.3+ Months 60 50 40 30 20 20% Tumor Growth 10 0 -10 -20 -30 30% Tumor Reduction -40 -50 -60 -70 -80 -90 -100 0 6

  12. Slide 12: Overall Survival

    Slide 12: Overall Survival

    OVERALL SURVIVAL 12-month OS, % (95% CI) Median OS, Months (95% CI) Median F/U, Months (Range) No Active Liver Mets EE (n=69) 74% (59–84) 20.9 (20.9–NR)​ 9.8 (1.4–36.5) Active Liver Mets EE (n=18) 30% (11–52) 8.7 (6.1–NR) 7.8 (2.3–21.7) All EE (n=87) 62% (49–73) 20.9 (10.6–NR) 9.3 (1.4–36.5) ITT (N=

  13. Slide 13: Safety: All TEAEs in ≥15% of ITT Population

    Slide 13: Safety: All TEAEs in ≥15% of ITT Population

    SAFETY All TEAEs in ≥15% of the ITT Population (N=101) TEAE, n (%) All Grades Grade 3 Grade 4 TEAE, n (%) All Grades Grade 3 Grade 4 Any* 101 (100) 58 (57) 4 (4) Musculoskeletal Gastrointestinal Arthralgia 24 (24) 1 (1) 0 Diarrhea 50 (50) 8 (8) 0 Skin Nausea 41 (41) 5 (5) 0 Pruritus 24 (24) 0 0 Vomi

  14. Slide 14: Safety: All TRAEs in ≥15% of ITT Population

    Slide 14: Safety: All TRAEs in ≥15% of ITT Population

    SAFETY All TRAEs in ≥15% of the ITT Population (N=101) TRAE, n (%) All Grades Grade 3 Grade 4 Any* 89 (88) 37 (37) 2 (2) Gastrointestinal Immune-mediated diarrhea/colitis* 40 (40) 16 (16) 1 (1) Nausea 20 (20) 2 (2) 0 • No new safety signals Constitutional • Safety in CRC consistent across Fatigue 32

  15. Slide 15: Conclusions & Future Directions

    Slide 15: Conclusions & Future Directions

    CONCLUSIONS & FUTURE DIRECTIONS • Botensilimab is a multifunctional CTLA-4 antibody with broad activity in “cold” or I-O refractory tumors • Botensilimab plus balstilimab continues to show deep and durable objective responses and notable overall survival compared to historical data in non-MSI-H CRC

  16. Slide 16: Acknowledgements and Abbreviations

    Slide 16: Acknowledgements and Abbreviations

    ACKNOWLEDGEMENTS ABBREVIATIONS Agenus Inc. funded and is the AE, adverse event APC, antigen presenting cell​​ IgG, immunoglobulin G​ I-O, immunotherapy​ legal entity responsible for this study. bal, balstilimab BOR, best overall response​ ITT, intent-to-treat mAb, monoclonal antibody​ Mets, metastas

  17. Slide 17: Q&A Session

    Slide 17: Q&A Session

    JORLD CONGRESS ON Snteeall Gastrointestinal swim Cancer Q&A Session

Source: Internet Archive copy of agenusbio.com

More decks from Agenus Inc.

All 34 Agenus decks